Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $1.3B | $958M | $180M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $8M | $15M | $144M | $3M | $1M | — |
| Bruttoergebnis | $1.2B | $902M | $174M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | ($1M) | ($1M) | ($1M) | $6M | $15M | $141M | $3M | $1M | ($4M) |
| Bruttomarge % | 91.5% | 94.1% | 96.5% | — | — | — | — | — | — | 100.0% | — | — | — | — | -502.0% | 80.7% | 100.0% | 97.4% | 100.0% | 100.0% | — |
| Betriebsergebnis (EBIT) | ($323M) | ($300M) | ($498M) | ($380M) | ($294M) | ($242M) | ($207M) | ($95M) | ($41M) | ($32M) | ($25M) | ($3M) | ($84M) | ($88M) | ($61M) | ($45M) | ($37M) | $81M | ($94M) | ($66M) | ($59M) |
| Operative Marge % | -25.2% | -31.3% | -276.4% | — | — | — | — | — | — | -9160.6% | — | — | — | — | -41556.5% | -599.0% | -249.3% | 55.8% | -3583.5% | -8912.0% | — |
| Jahresüberschuss | ($325M) | ($288M) | ($466M) | ($374M) | ($295M) | ($241M) | ($197M) | ($73M) | ($33M) | ($31M) | ($26M) | ($7M) | ($86M) | ($90M) | ($63M) | ($47M) | ($37M) | $79M | ($93M) | ($63M) | ($57M) |
| Nettomarge % | -25.3% | -30.1% | -258.6% | — | — | — | — | — | — | -8901.1% | — | — | — | — | -42714.3% | -624.7% | -253.1% | 54.8% | -3541.8% | -8545.8% | — |
| EBITDA | — | ($264M) | ($450M) | ($360M) | ($291M) | ($242M) | ($206M) | ($95M) | ($41M) | ($32M) | ($25M) | ($3M) | ($83M) | ($87M) | ($60M) | ($44M) | ($35M) | $82M | ($89M) | ($60M) | ($54M) |
| Ergebnis je Aktie (EPS) | $-12.93 | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.58 | $-12.78 | $-4.73 | $-2.22 | $-2.54 | $-5.07 | $-40.03 | $-30.62 | $-44.47 | $-37.00 | $-35.15 | $-32.50 | $81.13 | $-96.09 | $-68.45 | $-90.03 |
| Ausstehende Aktien (Mio.) | — | 22M | 21M | 19M | 17M | 17M | 15M | 15M | 15M | 12M | 5M | 0M | 3M | 2M | 2M | 1M | 1M | 1M | 1M | 1M | 1M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für MDGL. /companies/us/MDGL
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms